1. Executive Summary
1.1 Top Biosimilar Drug Manufacturers: Overview of Findings
1.2 Report Contents
1.3 Report Methods
1.4 Scope and Format of Report
2. World Biosimilar Drugs Market 2012-2022: An Introduction
2.1 Introduction to Biologics and Biosimilars
2.1.1 Classes of Biologic and Biosimilar Drugs
2.2 The World Biosimilar Drugs Market 2012-2022
2.2.2 The World Biosimilar Drugs Market Forecast 2012-2022
2.3 What Will Drive Biosimilar Drugs Market Growth Between 2012 and 2022?
2.4 Restraints Exist for the Biosimilar Drugs Market Between 2012 and 2022
2.5 Leading Companies in the Biosimilars Market 2011
2.5.1 How Will the Top 25 Ranking Change Between 2012 and 2022?
3. Top Biosimilar Manufacturers in Developed Markets 2012-2022
3.1 Sandoz: The Biosimilars Market Leader 2012
3.1.1 Three Biosimilars Marketed Worldwide
3.1.1.1 Omnitrope (Somatropin): A Global Biosimilar Brand
3.1.1.2 Binocrit (Epoetin Alpha)
3.1.1.3 Zarzio (Filgrastim)
3.1.2 Revenue Growth 2008-2011
3.1.3 Biosimilars Pipeline 2012
3.1.3.1 Biosimilar Rituximab: First to Market in the EU?
3.1.4 Sandoz: Biosimilars Market Outlook
3.1.4.1 Sandoz: Biosimilars SWOT Analysis 2012-2022
3.1.4.2 Will Sandoz be the Biosimilars Market Leader in 2022?
3.2 Teva
3.2.1 Biosimilar Product Portfolio
3.2.1.1 Tevagrastim (Filgrastim)
3.2.1.2 Eporatio (Epoetin Theta)
3.2.1.3 Teva Acquires Ratiopharm
3.2.1.4 Expansion in Eastern Europe: Teva Acquires Sicor Biotech
3.2.2 Oncology Biosimilars Drive Revenue Growth 2009-2011
3.2.3 Teva to Launch Biosimilars in Japan
3.2.4 Biosimilars Pipeline 2012
3.2.4.1 Teva Collaborates with Lonza to Develop Biosimilar Rituximab
3.2.4.2 Teva Will be First to Launch Biosimilar Filgrastim in the US
3.2.5 Teva: Biosimilars Market Outlook
3.2.5.1 Broad Market Access for Growth Opportunities
3.2.5.2 Compare Teva's Revenue Growth with Sandoz 2012-2022
3.3 Hospira
3.3.1 Biosimilar Product Portfolio
3.3.2 Which Biosimilar Products is Hospira Developing?
3.3.2.1 Developing Biosimilars for the US Market
3.3.2.2 Alliance with Celltrion for Biosimilar Monoclonal Antibodies
3.3.3 Hospira: Biosimilars Market Outlook
3.3.3.1 Hospira: Biosimilars SWOT Analysis 2012-2022
3.4 Stada Arzneimittel
3.4.1 Silapo (Epoetin Zeta)
3.4.2 Performance of Silapo in the EU 2008-2011
3.4.3 Biosimilar Monoclonal Antibodies in Development
3.4.3.1 Collaboration with Gedeon Richter 2011
3.4.4 Stada: Biosimilars Market Outlook
3.4.4.1 Alliances over In-House Development for Future Growth
3.4.4.2 Stada: Biosimilar Revenue Forecast 2012-2022
3.5 Medice Arzneimittel Pütter
3.5.1 Medice Markets One Biosimilar in the EU
3.5.2 Medice: Biosimilars Market Outlook
3.6 JCR Pharmaceuticals: The Leading Japanese Market Player
3.6.1 Epoetin Alfa BS Inj. JCR: Japan's Second Biosimilar
3.6.2 Alliance with GSK
3.6.3 Biosimilars Pipeline 2012
3.6.4 JCR Pharmaceuticals: Biosimilars Market Outlook
3.7 New Market Entrants to Compete Strongly to 2022
3.7.1 Watson Pharmaceuticals Set to Enter the Biosimilar Insulin Market
3.7.2 Mylan: Another Global Generics Manufacturer Developing Biosimilars
3.7.3 Big Pharma's Involvement in Biosimilars
3.7.3.1 Pfizer: Exploiting Alliances and Internal Biosimilar Development for Market Entry
3.7.3.2 Boehringer Ingelheim
3.7.4 Local Manufacturers Looking to Enter the Japanese Market
3.7.4.1 Mochida Pharmaceutical
3.7.4.2 Nichi-Iko Pharmaceutical Partners with Sanofi for Biosimilars
3.7.4.3 Nippon Kayaku
4. Top Chinese Biosimilar Manufacturers 2012-2022
4.1 3SBio: China's Leading Biosimilars Manufacturer
4.1.1 Biosimilar Product Portfolio
4.1.1.1 EPAIO (Erythropoietin)
4.1.2 3SBio is Dominant in the Chinese EPO Market
4.1.3 Biosimilars Pipeline 2012
4.1.4 3SBio: Biosimilars Market Outlook
4.1.4.1 How Will Novel Drug Development Affect 3SBio's Biosimilar Performance?
4.1.4.2 3SBio: Biosimilar Revenue Forecast 2012-2022
4.2 Beijing SL Pharmaceutical
4.2.1 Specialising in Niche Biosimilars
4.2.2 Biosimilar Financial Performance 2011
4.2.3 Biosimilars Pipeline 2012
4.2.4 Beijing SL Pharmaceutical: Biosimilars Market Outlook
4.2.4.1 Targeting Monoclonal Antibodies for Future Growth
4.3 GeneScience Pharmaceuticals (GenSci)
4.3.1 Biosimilar Product Portfolio
4.3.1.1 Jintropin (Somatropin): A Low-Cost Growth Hormone
4.3.2 Three Biosimilars in Development 2012
4.3.3 GeneScience Pharmaceuticals: Biosimilars Market Outlook
4.3.3.1 Product Launches in 2013-2014 to Drive Growth
4.4 Shanghai Fosun Pharmaceutical
4.4.1 Shanghai Fosun's Biosimilar Insulin
4.4.2 Rapid Revenue Growth 2008-2009
4.4.3 Shanghai Fosun Pharmaceutical: Biosimilars Market Outlook
4.4.3.1 Will Insulin Analogues Maintain Shanghai Fosun's Market Share?
4.5 Tonghua Dongbao
4.5.1 Biosimilar Product Portfolio
4.5.2 Expanding Manufacturing Capacity to Cope with Increased Demand
4.5.3 Biosimilars Pipeline 2012
4.5.4 Tonghua Dongbao: Biosimilars Market Outlook
4.5.4.1 Tonghua Dongbao to Launch Insulin Analogues in 2015
4.6 The Chinese Biosimilars Market is Competitive - Many New Companies Will Enter by 2022
4.6.1 Can United Laboratories Gain Significant Insulin Market Share?
4.6.2 Shanghai CP Goujian Pharmaceutical Leads Biosimilar Monoclonal Antibody Development
5. Top Indian Biosimilar Manufacturers 2012-2022
5.1 Biocon
5.1.1 Biosimilar Product Portfolio
5.1.1.1 Basalog: Biocon's First Insulin Analogue
5.1.2 Alliances for Entering Developed Markets
5.1.2.1 Biocon Acquires, and Sells, a Stake in AxiCorp
5.1.2.2 Pfizer: An Abandoned Biosimilar Insulin Collaboration
5.1.2.3 Biocon Partners with Mylan for Oncology Biosimilars
5.1.3 Biosimilars Pipeline 2012
5.1.4 Biocon: Biosimilars Market Outlook
5.1.4.1 Insulin and Monoclonal Antibodies: Two Key Market Sectors to Drive Growth for Biocon
5.2 Dr. Reddy's Laboratories
5.2.1 Biosimilar Product Portfolio
5.2.1.1 Reditux (Rituximab): India's First Biosimilar Monoclonal Antibody
5.2.2 Biosimilar Revenue Growth Outpaces Generic Revenue Growth 2011-2012
5.2.3 Alliance with Merck KGaA to Enter Developed Markets
5.2.4 Seven New Biosimilars to Launch by 2018
5.2.5 Dr. Reddy's Laboratories: Biosimilars Market Outlook
5.2.5.1 Opportunities Exist for Continued Biosimilar Growth 2012-2022
5.2.5.2 Dr. Reddy's Laboratories: Rapid Revenue Growth 2012-2022
5.3 Intas Biopharmaceuticals
5.3.1 Five Biosimilars Launched Since 2004
5.3.2 Filgrastim for Developed Markets: Alliance with Apotex
5.3.3 Intas Has the Longest Biosimilar Antibody Pipeline in India
5.3.4 Intas Biopharmaceuticals: Biosimilars Market Outlook
5.3.4.1 Biosimilars vs. Biobetters: Two Future Biological Drug Development Strategies
5.4 Reliance Life Sciences
5.4.1 Reliance Has Launched Seven Biosimilars in Three Years
5.4.2 Reliance GeneMedix: A Developed Market Subsidiary
5.4.3 Biosimilars Pipeline 2012
5.4.4 Reliance Life Sciences: Biosimilars Market Outlook
5.4.4.1 Can Reliance Continue its Rapid Growth in the Biosimilars Market?
5.5 Wockhardt
5.5.1 Wockhardt: Focused on Biosimilar Insulin
5.5.1.1 Wosulin
5.5.1.2 Glaritus: The World's First Biosimilar Insulin Glargine
5.5.2 Biosimilars Pipeline 2012
5.5.3 Wockhardt: Biosimilars Market Outlook
5.5.3.1 More Biosimilar Launches Expected Beyond 2015
5.6 Zydus Cadila
5.6.1 A Long History in Biosimilars
5.6.2 Twelve Biosimilars in Development 2012
5.6.3 Zydus Cadila: Biosimilars SWOT Analysis 2012-2022
5.7 More Generics Manufacturers Will Enter the Market from 2012
5.7.1 Ranbaxy Laboratories and Zenotech Laboratories Market Three Biosimilars
5.7.2 Cipla: Developing Biosimilars Since 2004
5.7.3 Lupin Pharmaceuticals
6. Top Latin American Biosimilar Manufacturers 2012-2022
6.1 Probiomed
6.1.1 Biosimilar Products Marketed Since 1998
6.1.2 Probiomed Plans to Enter the Brazilian Market
6.1.3 Probiomed Launch Biosimilar Rituximab
6.1.4 Probiomed: Biosimilars Market Outlook
6.1.4.1 Expanding its Mature Biosimilar Portfolio to New Markets for New Opportunities 2012-2022
6.2 Biosidus
6.2.1 Two Decades of Biosimilar Market Experience
6.2.2 Facility Expansion to Meet Increased Demand 2008-2010
6.2.3 Two Biosimilars in Late-Stage Development 2012
6.2.4 Biosidus: Biosimilars Market Outlook 2012-2022
6.2.4.1 Biosidus: Biosimilars SWOT Analysis 2012-2022
6.3 Amega Biotech
6.3.1 Biosimilar Product Portfolio
6.3.2 Investment in New Manufacturing Facilities 2011-2012
6.3.3 Which New Biosimilars is Amega Biotech Developing?
6.3.4 Amega Biotech: Biosimilars Market Outlook
6.3.4.1 New Product Launches and New Markets as Growth Opportunities
6.4 Aché
6.4.1 Biosimilar Product Portfolio
6.4.2 Bionovis: Collaboration for Revenue Growth
6.4.3 Biosimilars Pipeline 2012
6.4.4 Aché: Biosimilars Market Outlook
6.4.4.1 How Will Aché's Biosimilar Portfolio Perform During This Decade?
6.5 Latin America: Emerging National Markets Providing Opportunities for New Entrants 2012-2022
7. Top Biosimilar Manufacturers in Central and Eastern Europe (CEE) and Russia 2012-2022
7.1 Bioton: Biosimilar Insulin for Emerging Markets
7.1.1 Biosimilar Product Portfolio
7.1.1.1 Gensulin
7.1.1.2 Biosimilars in Developed Markets: Biopartners
7.1.1.3 Biosimilars in Asia: SciGen
7.1.2 Insulin and Other Biosimilars: Revenue Performance 2010-2011
7.1.3 Bioton and the Chinese Insulin Market
7.1.4 Alliance with Actavis to Bring Gensulin to Developed Markets
7.1.5 Bioton: Biosimilars Market Outlook
7.1.5.1 How Will Watson's Acquisition of Actavis Impact Bioton?
7.1.5.2 Bioton: Biosimilar Revenue Forecast 2012-2022
7.2 Pharmstandard
7.2.1 Three Biosimilars Marketed in Russia
7.2.1.1 International Biotech Center (IBC) Generium
7.2.2 Above-Market Revenue Growth 2010-2011
7.2.3 Pharmstandard Has Expanded its Market Presence Through Strategic Acquisitions
7.2.4 Pharmstandard: Biosimilars Market Outlook
7.2.4.1 Pharmstandard: Biosimilars SWOT Analysis 2012-2022
7.2.4.2 Incorporation of New Subsidiaries to Drive Revenue Growth 2012-2022
7.3 CEE and Russia: Biosimilar Competitor Analysis 2012-2022
7.3.1 Gedeon Richter: Two Monoclonal Antibodies in Development
7.3.2 Egis Pharmaceuticals
8. Top South Korean Biosimilar Manufacturers 2012-2022
8.1 LG Life Sciences: An Emerging Market Leader
8.1.1 Expertise in Fertility
8.1.2 How Have LG's Biosimilars Performed in Recent Years?
8.1.3 Three Biosimilar Monoclonal Antibodies in Development
8.1.4 LG Life Sciences: Biosimilars Market Outlook
8.1.4.1 LG Life Sciences: Biosimilars SWOT Analysis 2012-2022
8.1.4.2 New Product Launches for Revenue Growth 2012-2022
8.2 Dong-A Pharmaceutical
8.2.1 Biosimilar Product Portfolio
8.2.2 Revenue Growth in South Korea and Brazil 2008-2011
8.2.3 Alliance with Meiji Seika Pharma to Enter the Japanese Market
8.2.4 Biosimilars Pipeline 2012
8.2.4.1 DA-3031 (Pegfilgrastim)
8.2.5 Dong-A Pharmaceutical: Biosimilars Market Outlook
8.2.5.1 Dong-A Pharmaceutical: Biosimilars SWOT Analysis 2012-2022
8.3 Many Companies Are Developing Biosimilar Monoclonal Antibodies in South Korea
8.3.1 Celltrion: A Partner for Many Biosimilar Developers Worldwide
8.3.2 Samsung Partners with Quintiles and Biogen Idec to Develop Biosimilars
9. Conclusions
9.1 Market Leaders 2011
9.2 Outlook for Market Leaders 2012-2022
9.3 New Competitors Entering the Market
List of Tables
Table 1.1 Currency Exchange Rates, 2011
Table 2.1 Biosimilar Drugs Market by Sector, 2011
Table 2.2 World Biosimilar Drugs Market: Overall Market and Sector Forecasts, 2011-2022
Table 2.3 Top Ten Biosimilar Manufacturers, by Revenue, 2011
Table 3.1 Leading Biosimilar Manufacturers in Developed Markets by Revenue, 2011
Table 3.2 Sandoz: Key Facts, 2012
Table 3.3 Sandoz: Biosimilar Revenue by Product, 2008-2011
Table 3.4 Sandoz: Biosimilars SWOT Analysis, 2012-2022
Table 3.5 Sandoz: Biosimilar Revenue Forecast, 2011-2022
Table 3.6 Teva: Key Facts, 2012
Table 3.7 Teva: Biosimilar Revenue, 2009-2011
Table 3.8 Teva: Biosimilars SWOT Analysis, 2012-2022
Table 3.9 Teva: Biosimilar Revenue Forecast, 2011-2022
Table 3.10 Hospira: Key Facts, 2012
Table 3.11 Hospira: Biosimilars SWOT Analysis, 2012-2022
Table 3.12 Stada: Key Facts, 2012
Table 3.13 Stada: Biosimilar Revenue, 2008-2011
Table 3.14 Stada: Biosimilars SWOT Analysis, 2012-2022
Table 3.15 Stada: Biosimilar Revenue Forecast, 2011-2022
Table 3.16 Medice: Key Facts, 2012
Table 3.17 JCR Pharmaceuticals: Key Facts, 2012
Table 3.18 JCR Pharmaceuticals: Biosimilars SWOT Analysis, 2012-2022
Table 3.19 Big Pharma and the Biosimilars Market, 2012
Table 4.1 Selected Chinese Biosimilar Manufacturers and their Activities, 2012
Table 4.2 3SBio: Key Facts, 2012
Table 4.3 3SBio: Biosimilar Revenue by Product, 2009-2011
Table 4.4 3SBio: Biosimilars SWOT Analysis, 2012-2022
Table 4.5 3SBio: Biosimilar Revenue Forecast, 2011-2022
Table 4.6 Beijing SL Pharmaceutical: Key Facts, 2012
Table 4.7 Beijing SL Pharmaceutical: Biosimilars SWOT Analysis, 2012-2022
Table 4.8 GeneScience Pharmaceuticals: Key Facts, 2012
Table 4.9 GeneScience Pharmaceuticals: Biosimilars SWOT Analysis, 2012-2022
Table 4.10 Shanghai Fosun Pharmaceutical: Key Facts, 2012
Table 4.11 Chinese Insulin Market by Company, 2011
Table 4.12 Wanbang Biopharmaceuticals: Revenue, 2008-2009
Table 4.13 Shanghai Fosun Pharmaceutical: Biosimilars SWOT Analysis, 2012-2022
Table 4.14 Tonghua Dongbao: Key Facts, 2012
Table 4.15 Tonghua Dongbao: Biosimilars SWOT Analysis, 2012-2022
Table 5.1 Biocon: Key Facts, 2012
Table 5.2 Biocon: Biosimilars SWOT Analysis, 2012-2022
Table 5.3 Biocon: Biosimilar Discounts, 2011
Table 5.4 Dr. Reddy's Laboratories: Key Facts, 2012
Table 5.5 Dr. Reddy's Laboratories: Biosimilar Portfolio, 2012
Table 5.6 Reditux: Revenue 2008-2012
Table 5.7 Dr. Reddy's Laboratories: Biosimilar Revenue, 2011-2012
Table 5.8 Dr. Reddy's Laboratories: Biosimilars SWOT Analysis, 2012-2022
Table 5.9 Dr. Reddy's Laboratories: Biosimilar Revenue Forecast, 2011-2022
Table 5.10 Intas Biopharmaceuticals: Key Facts, 2012
Table 5.11 Intas Biopharmaceuticals: Biosimilar Product Portfolio, 2012
Table 5.12 Intas Biopharmaceuticals: Biosimilar Clinical Trials, 2012
Table 5.13 Intas Biopharmaceuticals: Biosimilars SWOT Analysis, 2012-2022
Table 5.14 Reliance Life Sciences: Key Facts, 2012
Table 5.15 Reliance Life Sciences: Biosimilar Product Portfolio, 2012
Table 5.16 Reliance Life Sciences: Biosimilars SWOT Analysis, 2012-2022
Table 5.17 Wockhardt: Key Facts, 2012
Table 5.18 Wockhardt: Biosimilars SWOT Analysis, 2012-2022
Table 5.19 Zydus Cadila: Key Facts, 2012
Table 5.20 Zydus Cadila: Biosimilar Product Portfolio, 2012
Table 5.21 Zydus Cadila: Biosimilar Pipeline, 2012
Table 5.22 Zydus Cadila: Biosimilars SWOT Analysis, 2012-2022
Table 6.1 Landsteiner Scientific: Marketed Biopharmaceuticals, 2012
Table 6.2 Probiomed: Key Facts, 2012
Table 6.3 Probiomed: Revenue, 2008-2011
Table 6.4 Probiomed: Biosimilars SWOT Analysis, 2012-2022
Table 6.5 Biosidus: Key Facts, 2012
Table 6.6 Biosidus: Biosimilars SWOT Analysis, 2012-2022
Table 6.7 Amega Biotech: R&D and Manufacturing Facilities, 2012
Table 6.8 Amega Biotech: Key Facts, 2012
Table 6.9 Amega Biotech: Revenue, 2009 & 2011
Table 6.10 Amega Biotech: Biosimilars SWOT Analysis, 2012-2022
Table 6.11 Aché: Key Facts, 2012
Table 6.12 Aché: Biosimilars SWOT Analysis, 2012-2022
Table 7.1 Bioton: Key Facts, 2012
Table 7.2 SciGen: Revenue by Country, 2011
Table 7.3 Bioton: Biosimilar Revenue by Company, H1 2010-2011
Table 7.4 Bioton: Biosimilars SWOT Analysis, 2012-2022
Table 7.5 Bioton: Biosimilar Revenue Forecast, 2011-2022
Table 7.6 Pharmstandard: Key Facts, 2012
Table 7.7 Pharmstandard: Insulin Manufacturing Capacity, 2010-2011
Table 7.8 Pharmstandard: Biosimilar Revenue by Product, 2009-2011
Table 7.9 Pharmstandard: Biosimilars SWOT Analysis, 2012-2022
Table 7.10 Pharmstandard: Biosimilar Revenue Forecast, 2011-2022
Table 8.1 LG Life Sciences: Key Facts, 2012
Table 8.2 LG Life Sciences: Biosimilar Revenue by Product, 2010-2011
Table 8.3 LG Life Sciences: Biosimilars SWOT Analysis, 2012-2022
Table 8.4 LG Life Sciences: Biosimilar Revenue Forecast, 2011-2022
Table 8.5 Dong-A Pharmaceutical: Key Facts, 2012
Table 8.6 Growtropin: Revenue, 2008-2011
Table 8.7 Dong-A Pharmaceutical: Biosimilar Export Revenue, 2009-2010
Table 8.8 Dong-A Pharmaceutical: Biosimilars SWOT Analysis, 2012-2022
Table 8.9 Celltrion: Biosimilar Licensing Deals, 2009-2010
Table 9.1 Biosimilars Market Leaders: Market Shares, 2011, 2016 and 2022
List of Figures
Figure 2.1 Biosimilar Drugs Market by Sector, 2011
Figure 2.2 Biosimilar Drugs Market Forecast, 2011-2022
Figure 2.3 Biosimilar Drugs Market by Sector, 2016
Figure 2.4 Biosimilar Drugs Market by Sector, 2022
Figure 2.5 World Biosimilar Drugs Market: Drivers and Restraints, 2012-2022
Figure 2.6 Top Ten Biosimilar Manufacturers by Revenue, 2011
Figure 3.1 Leading Biosimilar Manufacturers in Developed Markets by Revenue, 2011
Figure 3.2 Sandoz: Biosimilar Revenue by Product, 2008-2011
Figure 3.3 Sandoz: Biosimilar Revenue Forecast, 2011-2022
Figure 3.4 Sandoz: Biosimilars Market Share, 2011, 2016 and 2022
Figure 3.5 Teva: Biosimilar Revenue, 2009-2011
Figure 3.6 Teva: Biosimilar Revenue Forecast, 2011-2022
Figure 3.7 Teva: Biosimilars Market Share, 2011, 2016 and 2022
Figure 3.8 Stada: Biosimilar Revenue, 2008-2011
Figure 3.9 Stada: Biosimilar Revenue Forecast, 2011-2022
Figure 3.10 Stada: Biosimilars Market Share, 2011, 2016 and 2022
Figure 3.11 Developed Markets: Biosimilar Rituximab Development, 2012
Figure 4.1 3SBio: Biosimilar Revenue by Product, 2009-2011
Figure 4.2 3SBio: Biosimilar Revenue Forecast, 2011-2022
Figure 4.3 3SBio: Biosimilars Market Share, 2011, 2016 and 2022
Figure 4.4 Chinese Insulin Market by Company, 2011
Figure 4.5 Wanbang Biopharmaceuticals: Revenue, 2008-2009
Figure 5.1 Reditux: Revenue, 2008-2012
Figure 5.2 Dr. Reddy's Laboratories: Biosimilar Revenue, 2011-2012
Figure 5.3 Dr. Reddy's Laboratories: Biosimilar Revenue Forecast, 2011-2022
Figure 5.4 Dr. Reddy's Laboratories: Biosimilars Market Share, 2011, 2016 and 2022
Figure 6.1 Probiomed: Biosimilar Launches, 1998-2004
Figure 6.2 Probiomed: Revenue, 2008-2011
Figure 6.3 Amega Biotech: Revenue, 2009 & 2011
Figure 7.1 SciGen: Revenue by Country, 2011
Figure 7.2 Bioton: Biosimilar Revenue by Company, H1 2010-2011
Figure 7.3 Bioton: Biosimilar Revenue Forecast, 2011-2022
Figure 7.4 Bioton: Biosimilars Market Share, 2011, 2016 and 2022
Figure 7.5 Pharmstandard: Biosimilar Revenue by Product, 2009-2011
Figure 7.6 Pharmstandard: Biosimilar Revenue Forecast, 2011-2022
Figure 7.7 Pharmstandard: Biosimilars Market Share, 2011, 2016 and 2022
Figure 8.1 LG Life Sciences: Biosimilar Revenue by Product, 2010-2011
Figure 8.2 Biosimilar Monoclonal Antibody Progress in South Korea, 2012
Figure 8.3 LG Life Sciences: Biosimilar Revenue Forecast, 2011-2022
Figure 8.4 LG Life Sciences: Biosimilars Market Share, 2011, 2016 and 2022
Figure 8.5 Growtropin: Revenue, 2008-2011
Figure 8.6 Dong-A Pharmaceutical: Biosimilar Export Revenue, 2009-2010
Figure 9.1 Biosimilars Market Leaders: Market Shares, 2011, 2016 and 2022